BR0211604A - Integrin inhibitors for the treatment of eye disease - Google Patents

Integrin inhibitors for the treatment of eye disease

Info

Publication number
BR0211604A
BR0211604A BR0211604-9A BR0211604A BR0211604A BR 0211604 A BR0211604 A BR 0211604A BR 0211604 A BR0211604 A BR 0211604A BR 0211604 A BR0211604 A BR 0211604A
Authority
BR
Brazil
Prior art keywords
treatment
eye disease
integrin inhibitors
eye
integrin
Prior art date
Application number
BR0211604-9A
Other languages
Portuguese (pt)
Inventor
Hans Markus Bender
Jutta Haunschild
Ulrich Lang
Matthias Wiesner
Martin Friedlanger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0211604A publication Critical patent/BR0211604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

"INIBIDORES DE INTEGRINA PARA O TRATAMENTO DE DOENçAS DO OLHO". A presente invenção refere-se a métodos e composições para profilaxia e/ou tratamento de doenças do olho usando antagonistas dos receptores de integrina <244>~ v~<225>~ 3~ e/ou <244>~ v~<225>~ 5~. As composições podem ser nanopartículas e são administradas ao olho através de injeção no corpo vítreo do olho."INTEGRIN INHIBITORS FOR TREATMENT OF EYE DISEASES". The present invention relates to methods and compositions for prophylaxis and / or treatment of eye diseases using β4- and β2- and Î ± -244 integrin receptor antagonists. ~ 5 ~. The compositions may be nanoparticles and are administered to the eye by injection into the vitreous body of the eye.

BR0211604-9A 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye disease BR0211604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01
PCT/EP2002/007377 WO2003013511A1 (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
BR0211604A true BR0211604A (en) 2004-08-24

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211604-9A BR0211604A (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye disease

Country Status (20)

Country Link
US (2) US20040198644A1 (en)
EP (1) EP1411926B1 (en)
JP (1) JP2005504757A (en)
KR (1) KR20040028966A (en)
CN (1) CN1536998A (en)
AR (1) AR036199A1 (en)
AT (1) ATE296628T1 (en)
AU (1) AU2002319282B2 (en)
BR (1) BR0211604A (en)
CA (1) CA2456076C (en)
DE (1) DE60204466T2 (en)
DK (1) DK1411926T3 (en)
ES (1) ES2243744T3 (en)
HU (1) HUP0401605A3 (en)
MX (1) MXPA04000839A (en)
PL (1) PL207175B1 (en)
PT (1) PT1411926E (en)
RU (1) RU2311177C2 (en)
WO (1) WO2003013511A1 (en)
ZA (1) ZA200401598B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
ES2428896T3 (en) 2007-11-16 2013-11-12 Ube Industries, Ltd. Benzacepinone compound
CN102427816A (en) 2009-03-30 2012-04-25 宇部兴产株式会社 Pharmaceutical composition for treatment or prevention of ophthalmic diseases
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins Sustained delivery of therapeutic agents to an eye compartment
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
EA032552B1 (en) 2012-03-16 2019-06-28 Дзе Джонс Хопкинс Юниверсити Controlled release formulations for the delivery of hif-1 inhibitors
EA030318B1 (en) 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6064062B2 (en) 2013-03-15 2017-01-18 ファイザー・インク Indazole compounds that activate AMPK
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (en) * 2015-07-13 2017-06-16 서울대학교산학협력단 Compositions comprising nanoparticle-protein complex based on vitreous as an active ingredient for inhibiting angiogenesis, and uses thereof
CA3007198A1 (en) * 2015-12-04 2017-06-08 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
AU2017359027A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
KR102307767B1 (en) * 2019-03-11 2021-10-01 서울대학교병원 Integin αvβ3-targeted probe for diagnosing retinochoroidal neovascular disease and method for manufacturing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903921B2 (en) * 1995-08-14 2012-03-28 ザ スクリプス リサーチ インスティチュート Methods and compositions effective for inhibiting αVβ5-mediated angiogenesis
DE19538741A1 (en) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptide derivatives
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP2000516201A (en) * 1996-05-31 2000-12-05 ザ スクリップス リサーチ インスティテュート Method for inhibiting angiogenesis and composition useful for inhibiting angiogenesis
PL330241A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods of and compositions useful in inhibiting angiogenesis
DE19705450A1 (en) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclic aromatic amino acids
EP1061916A2 (en) * 1998-03-13 2000-12-27 Centaur Pharmaceuticals, Inc. Use os nitrone compounds for the inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (en) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon and chromanone derivatives
DE10006139A1 (en) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl derivatives

Also Published As

Publication number Publication date
US20060287225A1 (en) 2006-12-21
CA2456076C (en) 2011-08-23
DE60204466T2 (en) 2006-04-27
MXPA04000839A (en) 2004-05-14
US20040198644A1 (en) 2004-10-07
PT1411926E (en) 2005-10-31
ATE296628T1 (en) 2005-06-15
KR20040028966A (en) 2004-04-03
CA2456076A1 (en) 2003-02-20
US7645736B2 (en) 2010-01-12
DE60204466D1 (en) 2005-07-07
ES2243744T3 (en) 2005-12-01
HUP0401605A3 (en) 2012-09-28
PL367959A1 (en) 2005-03-07
AR036199A1 (en) 2004-08-18
RU2311177C2 (en) 2007-11-27
RU2004106527A (en) 2005-07-10
CN1536998A (en) 2004-10-13
EP1411926A1 (en) 2004-04-28
PL207175B1 (en) 2010-11-30
AU2002319282B2 (en) 2007-06-28
JP2005504757A (en) 2005-02-17
HUP0401605A2 (en) 2004-11-29
EP1411926B1 (en) 2005-06-01
DK1411926T3 (en) 2005-08-29
ZA200401598B (en) 2004-11-17
WO2003013511A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
BR0211604A (en) Integrin inhibitors for the treatment of eye disease
BR0316350A (en) Diaminotriazoles useful as protein kinase inhibitors
CY1107850T1 (en) THIADIAZYLOPIPERAZINE PRODUCT WITH USE IN APTROPIC OR IN ACTION AGAINST ALGUES
NO20025450D0 (en) New pharmaceutical composition
TNSN04165A1 (en) Substituted hydroxyethylamines
DE602004026053D1 (en)
DK0975595T3 (en) ***e analogs
ATE381537T1 (en) FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
WO2004094384A3 (en) (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
TR200901979T2 (en) Novel drug compositions based on anticholinergically effective compounds and? -Mimetics.
NO20050851L (en) Caspase Inhibitors and Uses thereof
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
EP2037739A4 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
BR0012175A (en) Igiur5 receptor antagonists, selective for the treatment of migraine
WO2005056524A3 (en) Therapeutic agents useful for treating pain
BR0309486A (en) A compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, and a method for treating a condition associated with excess tachykinins.
BR0115077A (en) Methods and compositions for treating eye disease
MY139203A (en) Pharmaceutical composition
BR0307627A (en) Methods and compositions for treating eye diseases
BR0315777A (en) Use of piperazine derivatives as ccr1 antagonists
DE60234919D1 (en) 3, 7 OR 3 AND 7 THIA- OR OXAPROSTANIC ACIDS DERIVATIVES AS A MEANS FOR REDUCING EYE REMINDER
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
ATE369348T1 (en) CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY
BR0201974A (en) Pharmaceutical composition for treating sleep disorders
BR0315837A (en) Heteroaryl hexanoic acid amide derivatives as immunomodulatory agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.